Bepotastine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Bepotastine
Bepotastine: Known uses and market status in Canada
Summary
The TxGNN model produced candidates for Bepotastine, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is listed below with its source.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| allergic urticaria | official label (curated); approved indication: urticaria |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02456532 | BEPREVE | Valid |
Safety Considerations
- Hypersensitivity: Rare case reports describe urticaria triggered by bepotastine itself, with cross-reactivity to other antihistamines. Patients with a history of antihistamine-induced urticaria need careful assessment.
- Sedation: Large-scale surveillance of H1-antihistamines identifies sedation as the most frequent side effect of the class.
Please refer to the package insert for full warnings, contraindications and drug interaction information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.